FDA Grants Traditional Approval to Tarlatamab-dlle for Extensive Stage Small Cell Lung Cancer By Ogkologos - January 22, 2026 353 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the DeLLphi-304 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR Combination of Azacitidine and Venetoclax in Previously Untreated AML August 18, 2020 EMA Recommends Granting a Marketing Authorisation for Azacitidine May 3, 2021 Similar Median OS Between Ripretinib versus Sunitinib in Patients with Advanced... June 2, 2025 ESMO Announces Results of 2025 Elections June 14, 2025 Load more HOT NEWS Long-Term Benefit of Sotorasib in Patients with Pretreated KRASG12C-Mutated NSCLC EMA Recommends Granting a Marketing Authorisation for Poherdy CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated... Large Study Confirms that HPV Vaccine Prevents Cervical Cancer
